NKX-101

N/A

Report date: 2024/04/18 13:54:23

Base Information

Drug NameNKX-101

Drug Alias NameCAR NKG2D NK cellsNKG2DNKX-101

ClassificationCell and gene therapy > Gene therapyCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > Natural killer cell therapy > Chimeric antigen receptor NK cell therapy

Mechanisms of ActionImmunologic cytotoxicityNatural killer cell replacementsNKG2D ligands antagonists

TargetsNKG2D ligands

Therapy Area/IndicationsMyelodysplastic SyndromesLeukemia, Promyelocytic, AcuteLeukemia, Myeloid, Acute

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryUnited States

CombinationsNo

Global Highest StatusPhase 1 Clinical

Highest Status in ChinaN/A

Originator CompaniesNkarta Inc

China Registration ClassN/A

Develop Information

Active CompaniesNkarta Inc

Inactive CompaniesN/A

Active IndicationsMyelodysplastic SyndromesLeukemia, Promyelocytic, AcuteLeukemia, Myeloid, Acute

Inactive IndicationsN/A

Other Information

ATC CodeN/A